Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
NCT06517693
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HIV-1
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- Up to 72 Hours
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Last updated on ClinicalTrials.gov
- August 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Site 5052, University of Colorado Denver · Aurora, CO
Florida · 1
- Site 5051, University of Florida Jacksonville · Jacksonville, FL
Maryland · 1
- Site 5092, Johns Hopkins University Baltimore · Baltimore, MD
New York · 1
- Site 5114, Bronx-Lebanon Hospital Center · The Bronx, NY
Texas · 1
- Site 5128, Baylor College of Medicine/Texas Children's Hospital · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.